مقاله انگلیسی رایگان در مورد پیشرفت در مهندسی بافت و سلول های بنیادی – Liebertpub 2012

samplepic2

 

مشخصات مقاله
ترجمه عنوان مقاله پیشرفت در مهندسی بافت و سلول های بنیادی “آیا ما هنوز آنجا هستیم؟”
عنوان انگلیسی مقاله Progress in the Tissue Engineering and Stem Cell Industry “Are we there yet?”
انتشار  مقاله سال ۲۰۱۲
تعداد صفحات مقاله انگلیسی  ۱۲ صفحه
هزینه  دانلود مقاله انگلیسی رایگان میباشد.
پایگاه داده  نشریه liebertpub
نوع نگارش مقاله مقاله مروری (Review article)
مقاله بیس این مقاله بیس نمیباشد
نمایه (index) scopus – master journal – MedLine
نوع مقاله
ISI
فرمت مقاله انگلیسی  PDF
ایمپکت فاکتور(IF)
۳٫۵۰۸ در سال ۲۰۱۷
رشته های مرتبط  پزشکی – زیست شناسی
گرایش های مرتبط  مهندسی بافت – علوم سلولی و مولکولی
نوع ارائه مقاله
ژورنال
مجله / کنفرانس مهندسی بافت بخش B: بررسی ها – Tissue Engineering Part B: Reviews
دانشگاه Department of Chemical Engineering and the David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.
شناسه دیجیتال – doi https://doi.org/10.1089/ten.teb.2011.0553
کد محصول E11659
وضعیت ترجمه مقاله  ترجمه آماده این مقاله موجود نمیباشد. میتوانید از طریق دکمه پایین سفارش دهید.
دانلود رایگان مقاله دانلود رایگان مقاله انگلیسی
سفارش ترجمه این مقاله سفارش ترجمه این مقاله

 

 

بخشی از متن مقاله:

This report presents a detailed update to our 2008 publication on the tissue engineering (TE) and stem cell industry. Data are reported through mid 2011 showing an almost three-fold growth in commercial sales over the past 4 years. In addition, the number of companies selling products or offering services has increased over twofold to 106, and they are generating a remarkable $3.5 billion in sales. Overall, the TE and stem cell sector is spending $3.6 billion and employing almost 14,000 employees. These data suggest the TE and stem cell industry has stabilized and is on a path pointing toward continued success.

Introduction

The tissue engineering (TE) industry has hardly traveled a smooth path toward success, experiencing a roller coaster ride over the last quarter century. The late Michael Lysaght devoted five articles analyzing this path over time, the first reported in 1995 and the last in 2008.1–۵ Lysaght’s analyses outlined the emergence and hype, growth, downward trend, and rebound of the field and are eloquently summarized in Nerem’s article.6 Briefly, the TE industry began to develop in earnest in the 1990s and grew to 3300 full time employees (FTEs) working in over 70 companies at the end of 2000.1 By 2001, a number of TE products had reached the market, including Organogenesis’ Apligraf and Genzyme’s Carticel. Expectations and hype were high both in the science and TE business communities and in the news. In 1999, a Good Morning America report described TE as one of the greatest scientific accomplishments of the 20th century.7 Soon after the turn of the century, however, the industry entered a dark period. Private sector activity decreased 20% and the capital value of publicly traded TE companies fell a staggering 90 percent.4 This was in part due to a poor economy and the consequent decrease in investor interest, and also due to failed product launches and disappointing results from Food and Drug Administration (FDA) clinical trials. Incredibly, the industry had rebounded by our 2008 report and was back on track to meet the expectations set in the ’۹۰s.3 The capital values for public TE companies increased over 10-fold compared to 2003 and products were entering FDA clinical trials, achieving FDA-approval, and in some cases becoming profitable. Today, as the data reported here indicate, the industry is on a path pointing toward continued success.

ارسال دیدگاه

نشانی ایمیل شما منتشر نخواهد شد.